Diabetes decisions — 2025

The Board denied the claims for service connection for diabetes mellitus type II, bladder cancer, left and right leg peripheral neuropathy as there was no evidence of in-service incurrence or aggravation of a disease or injury, and no causal relationship between the current disabilities and the Veteran's military service.

The Board remands the claims for service connection for a heart disorder and diabetes mellitus, to include as due to ionizing radiation exposure, as there has not been substantial compliance with previous remand directives.

The Board remands the claims for service connection for diabetes mellitus and bilateral plantar fasciitis with bunions for further development, including obtaining private treatment records and line of duty determinations.

The Board granted service connection for bilateral hearing loss and diabetes mellitus type II, finding that the Veteran was exposed to herbicide agents during his service in Guam.

The Board granted service connection for diabetes mellitus type II, ischemic heart disease, and hypertension on a presumptive basis due to herbicide exposure.

The Veteran's migraine headaches are granted a 50 percent rating, and the right eyebrow scar is granted a separate 10 percent rating for pain. The other service connection claims are remanded.

The Board denied the Veteran's August 2023 Application for Disability Compensation and Related Compensation Benefits (VA Form 21-526EZ) as it was the incorrect form to file when seeking to reopen previously denied claimed disorders.

The Board granted service connection for diabetes mellitus type II, hypertension, and renal failure due to presumed exposure to herbicide agents during the Veteran's service in Thailand. The claims for hearing loss, skin rashes, hepatitis C, and TDIU were remanded.

The Board denied service connection for diabetes mellitus and mild gynecomastia of the left breast as there was insufficient evidence to establish a nexus between these conditions and toxic exposure during service.

The Board granted service connection for an acquired psychiatric disability, diabetes mellitus, type 2, and erectile dysfunction secondary to diabetes. However, the claims for bronchitis, obstructive sleep apnea, and peripheral vascular disease were dismissed.

The Board remands the issues for further development, including obtaining a new TERA memorandum and appropriate VA opinions to determine if the Veteran's claimed conditions are related to his service exposure.

The Board denied the veteran's claims for service connection for diabetes mellitus, type II and hypertension as there was no evidence of a nexus between the claimed in-service disease or injury and the current disabilities.

The Board remands the claim for service connection for diabetes mellitus, Type 2 (DM II) to obtain a medical opinion addressing whether the appellant's current DM II is related to his conceded toxic exposure under the PACT Act.

The Board granted earlier effective dates of August 10, 2022, for the grants of service connection for right and left lower extremity diabetic peripheral neuropathy and diabetic retinopathy. The claim for an increased rating for diabetes mellitus, type II, with erectile dysfunction was denied.

The Board remands the veteran's claims for increased ratings and other benefits due to incomplete records.

The Board denied a rating in excess of 20 percent for diabetes mellitus type II but granted service connection for a neurological disorder, claimed as blackouts, essential tremors, memory loss.

The Board denied service connection for various disabilities, including prostate disability (BPH), nummular eczema, nephrolithiasis, neuropathy in both upper and lower extremities, and pseudophakia as secondary to diabetes mellitus, type II, due to a lack of evidence supporting a causal relationship between the disabilities and the Veteran's active service, including herbicide agent exposure.

The Board denied service connection for autoimmune arthritis and denied initial ratings in excess of 10 percent, 60 percent, and 20 percent for atrial fibrillation, coronary artery disease, and diabetes mellitus, respectively. The Board also denied an initial compensable rating for a residual scar associated with CAD and denied initial ratings in excess of 10 percent for bilateral lower extremity femoral and sciatic nerve neuropathies.

The Board granted an effective date of August 21, 2019, for the assignment of a 100 percent rating for PTSD with depressive disorder and granted service connection for headaches and vertigo as secondary to the service-connected PTSD.

The Board granted an earlier effective date of April 28, 2021, for the award of service connection for bilateral upper and lower extremity diabetic neuropathies.